Search
Roger joined Seagen as Chief Medical Officer in 2018, bringing extensive experience in cancer drug development. His deep oncology background and proven leadership has helped Seagen evolve into a global, multi-product oncology company.
Previously, Roger was Therapeutic Area Head for Late-Stage Oncology at Merck & Co., Inc., where he was responsible for registration efforts for Keytruda® (pembrolizumab) across multiple tumor types. Earlier in his career, Roger was the Vice President of Oncology Clinical Research at Gilead Sciences and the Global Development Lead for Xgeva® (denosumab) at Amgen, where he held multiple roles in oncology and hematology.
Roger holds an M.D. from the University of Witwatersrand in Johannesburg, South Africa. He serves as a member of the board of directors for INOVIO Pharmaceuticals, Inc.
